Written questions by Pochin.

If he will make it his policy to maintain patient choice.

The Government is committed to giving patients greater control and choice over their care. Patients have a legal right to choose where they go for their first appointment when referred to consultant-led care as an outpatient.The Elective Reform Plan, published January 2025, sets out plans to improve patient choice, empowering people to take control of their health by making the NHS App and Manage Your Referral website the default route for patients to choose their provider. We are improving the information available to patients, such as waiting times. The 10-Year Health Plan sets out a transformed vision for elective care, that will ensure the National Health Service is receptive and reactive to patient preference, voice, and choice.In May 2023, NHS England asked all referrers to ensure they shortlist on average five choices from which the patient may choose, where this is practicable, clinically appropriate, and preferred by the patient. Integrated care boards have responsibility to ensure that their patients are aware of the choices available to them and are able to exercise their legal right to choose a provider following an elective care referral, and this is underpinned in Part 8 of the NHS Standing Rules, which are available at the following link:https://www.legislation.gov.uk/uksi/2012/2996/part/8NHS England has regulatory oversight responsibilities to ensure patient choice operates effectively in the NHS and has published Patient Choice Guidance, which includes guidance for referrers, and which is available at the following link:https://www.england.nhs.uk/long-read/patient-choice-guidance/

What discussions he has had with integrated care boards and NHS England on ensuring that contracting decisions uphold the principles of patient choice.

The Government is committed to giving patients greater control and choice over their care. Patients have a legal right to choose where they go for their first appointment when referred to consultant-led care as an outpatient.Patients’ right to choose is set out in legislation. It is the responsibility of integrated care boards (ICBs) to make appropriate provision to meet the health and care needs of their local population and to meet their statutory obligations to promote choice and enable patients' legal rights.There is guidance for the use and implementation of the contractual levers available to ICBs, detailed in the NHS Standard Contract Technical Guidance. Use of these must not restrict patients' choice for provider.

What discussions he has had with integrated care boards and NHS England on ensuring that sufficient capacity is commissioned from independent sector providers to facilitate patient choice.

Integrated care boards (ICBs) have the flexibility to commission services across specialties within a fixed financial envelope and may use contract levers to manage that activity. This represents good management of public money to achieve the outcomes we want to see.Patients have a legal right to choose any qualified provider holding a contract with an ICB to deliver the services patients need. This right applies irrespective of levels of activity outlined in indicative activity plans contained in contracts.

What discussions he has had with NHS England and Integrated Care Board commissioners on the (a) fairness and (b) transparency of Indicative Activity Plans.

Indicative Activity Plans (IAPs) are non-binding, forecasted schedules under the NHS Standard Contract that define expected service volumes between commissioners for integrated care boards (ICBs) and providers. In setting these volumes, ICBs and providers are responsible for ensuring they do so with fairness and transparency.ICBs have contractual powers to manage activity by providers, which were enhanced in 2025/26 with central support for setting and managing activity. The NHS Standard Contract includes the ability to set IAPs to help providers and commissioners plan demand, capacity, and expenditure. While not binding, if activity exceeds, or falls short of the agreed plan, and therefore the funding agreed, an Activity Management Plan can be agreed to bring activity back in line.

What steps his Department is taking to help ensure that patients are offered a choice of five providers at the point of referral where appropriate.

The Government is committed to giving patients greater control and choice over their care. Patients have a legal right to choose where they go for their first appointment when referred to consultant-led care as an outpatient.The Elective Reform Plan, published January 2025, sets out plans to improve patient choice, empowering people to take control of their health by making the NHS App and Manage Your Referral website the default route for patients to choose their provider. We are improving the information available to patients, such as waiting times. The 10-Year Health Plan sets out a transformed vision for elective care, that will ensure the National Health Service is receptive and reactive to patient preference, voice, and choice.In May 2023, NHS England asked all referrers to ensure they shortlist on average five choices from which the patient may choose, where this is practicable, clinically appropriate, and preferred by the patient. Integrated care boards have responsibility to ensure that their patients are aware of the choices available to them and are able to exercise their legal right to choose a provider following an elective care referral, and this is underpinned in Part 8 of the NHS Standing Rules, which are available at the following link:https://www.legislation.gov.uk/uksi/2012/2996/part/8NHS England has regulatory oversight responsibilities to ensure patient choice operates effectively in the NHS and has published Patient Choice Guidance, which includes guidance for referrers, and which is available at the following link:https://www.england.nhs.uk/long-read/patient-choice-guidance/

How many civil servants are employed in his Department’s sponsor team for the NHS Business Services Authority by grade.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

What recent discussions he has had with the Chief Executive of the NHS Business Services Authority on the operation of the Vaccine Damage Payment Scheme.

The Department has been working with the NHS Business Services Authority (NHSBSA), the administrators of the scheme, to continue to take steps to improve the Vaccine Damage Payment Scheme (VDPS), including through improving claimants’ experiences and supporting engagement with healthcare providers to allow claims to be progressed to medical assessment at a faster rate. Officials have regular discussions with the NHSBSA on the operation of the VDPS.

What performance targets his Department has set for the processing of claims under the Vaccine Damage Payment Scheme.

The Department works closely with the NHS Business Services Authority (NHSBSA), the administrators of the Vaccine Damage Payment Scheme (VDPS), to improve claimants’ experiences. While no specific performance targets have been set for the processing of claims, the Department and NHSBSA are committed to continuing to make improvements to the scheme, including by supporting engagement with healthcare providers to allow claims to be progressed to medical assessment at a faster rate.Data from the NHSBSA shows as of 31 March 2026, there were 2,203 live VDPS claims, claims that are yet to receive an outcome. This is compared to 4,985 live claims as of 31 September 2025.

What timetable his Department has set for submitting proposals to the Cabinet Office on arm’s length body reform and accountability.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Whether his Department plans to assess the potential impact of changes to accreditation and registration requirements for counsellors introduced in December 2025 on (a) counsellors’ businesses, including their level of income and (b) waiting times for accreditation from professional bodies.

The Department does not set the qualification requirements for psychotherapy and counselling and was not involved in the changes to accreditation requirements introduced in December 2025. The Department does not receive any revenue or financial benefits arising from those changes.

Whether his Department received any revenue or financial benefit arising from the accreditation requirements for counsellors introduced in December 2025.

The Department does not set the qualification requirements for psychotherapy and counselling and was not involved in the changes to accreditation requirements introduced in December 2025. The Department does not receive any revenue or financial benefits arising from those changes.

What evidence his Department used to inform the decision to change accreditation requirements for counsellors in December 2025.

The Department does not set the qualification requirements for psychotherapy and counselling and was not involved in the changes to accreditation requirements introduced in December 2025. The Department does not receive any revenue or financial benefits arising from those changes.

Whether his Department has undertaken an impact assessment of the potential impact of the changes introduced in December 2025 to accreditation requirements for counsellors on the level of waiting times for patients seeking access to counselling services.

The Department does not set the qualification requirements for psychotherapy and counselling and was not involved in the changes to accreditation requirements introduced in December 2025. The Department does not receive any revenue or financial benefits arising from those changes.

What steps are being taken to guarantee access to specialist therapeutic support services for child victims of sexual abuse, in the context of the recommendation of the Independent Inquiry into Child Sexual Abuse.

Last April, we committed to ambitious proposals in response to recommendation 16 from the Independent Inquiry into Child Sexual Abuse. As part of our response to delivering on that promise, we are investing up to £50 million to roll out the internationally recognised Child House model across all National Health Service regions in England.The model brings health, justice, and social care professionals together under one roof to reduce trauma and deliver the care children deserve in a safe, child-centred environment. Too often, children are asked to retell their experiences to multiple professionals, reliving their trauma with each repetition. The Child House model changes this.This investment sits alongside our wider work to transform children’s mental health services. We are committed to reducing waiting times for specialist Child and Adolescent Mental Health Service support, as set out in our Medium-Term Planning Framework. We are accelerating the rollout of mental health support teams in schools and colleges, working towards full national coverage by 2029. And we are investing an additional £13 million to pilot enhanced training so school-based mental health teams can better support young people with complex needs, including trauma.Together, these actions represent a fundamental shift by treating child sexual abuse as the healthcare priority it is and ensuring that victims and survivors receive the very best support to rebuild their lives.

Whether NHS England plans to issue guidance to hospital trusts on providing reasonable parking adjustments for patient groups receiving frequent or intensive treatments, including those undergoing dialysis.

Decisions on the provision of car parking are made locally by National Health Service organisations and should be consistent with the national guidance. This includes the provision of parking adjustments for patient groups receiving frequent treatments, including those undergoing dialysis. Further information on the guidance is available at the following link:https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principlesThis guidance requires the provision of free hospital parking to groups classified as most ‘in-need’. This includes disabled people, frequent outpatient attenders, parents of sick children staying overnight, and NHS staff working overnight. These groups will include dialysis patients where applicable.

What assessment NHS England has made of the potential impact of withdrawing dedicated parking provision for dialysis patients on patient safety and treatment adherence.

Decisions on the provision of car parking are made locally by National Health Service organisations and should be consistent with the national guidance. This includes the provision of parking adjustments for patient groups receiving frequent treatments, including those undergoing dialysis. Further information on the guidance is available at the following link:https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principlesThis guidance requires the provision of free hospital parking to groups classified as most ‘in-need’. This includes disabled people, frequent outpatient attenders, parents of sick children staying overnight, and NHS staff working overnight. These groups will include dialysis patients where applicable.

Whether NHS England monitors local trust decisions on the withdrawal of designated parking arrangements for dialysis patients; and what mechanisms are in place to ensure such decisions take account of patient mobility and clinical vulnerability.

Decisions on the provision of car parking are made locally by National Health Service organisations and should be consistent with the national guidance. This includes the provision of parking adjustments for patient groups receiving frequent treatments, including those undergoing dialysis. Further information on the guidance is available at the following link:https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principlesThis guidance requires the provision of free hospital parking to groups classified as most ‘in-need’. This includes disabled people, frequent outpatient attenders, parents of sick children staying overnight, and NHS staff working overnight. These groups will include dialysis patients where applicable.

What assessment her Department has made of the potential merits of providing limited amounts of non-mRNA COVID-19 vaccines available for patients with clinical contraindications to mRNA vaccines, including through the importation of products already authorised by trusted international regulators.

The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:adults aged 75 years old and over;residents in care homes for older adults; andindividuals aged six months old and over who are immunosuppressed.As for all vaccines, the JCVI keeps all vaccination programmes under review.COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.

What assessment his Department has made of the potential merits of establishing a national referral pathway or specialist hub for people who cannot receive mRNA vaccines to ensure equitable access to appropriate COVID-19 vaccinations.

The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:adults aged 75 years old and over;residents in care homes for older adults; andindividuals aged six months old and over who are immunosuppressed.As for all vaccines, the JCVI keeps all vaccination programmes under review.COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.

How many people are clinically unable to receive mRNA-based COVID-19 vaccines; and how this figure has been derived.

The Government is committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). The primary aim of the national COVID-19 vaccination programme remains the prevention of serious illness, resulting in hospitalisations and deaths, arising from COVID-19.The Government has accepted the JCVI’s advice for autumn 2025 and in line with the advice, a COVID-19 vaccination is being offered to the following groups:adults aged 75 years old and over;residents in care homes for older adults; andindividuals aged six months old and over who are immunosuppressed.As for all vaccines, the JCVI keeps all vaccination programmes under review.COVID-19 vaccines are procured by the UK Health Security Agency (UKHSA) in line with JCVI advice.UKHSA advise that as with all vaccines there will be an extremely small proportion of people who cannot receive a particular COVID-19 vaccine due to an anaphylactic reaction, this includes mRNA vaccines. Advice published in the UKHSA Green Book recommends that anyone with a prior allergic reaction to COVID-19 vaccines should be seen by an expert allergist and, after a review of the individual’s risks and benefits of vaccination, where it is indicated, they could then be vaccinated in hospital under clinical supervision. Information is not held centrally on how many people seen under this pathway are unable to receive an mRNA COVID-19 vaccine even in a hospital setting. Where an allergist has advised that a vaccine is not suitable, and this is the only type of vaccine available in a particular campaign, the individual should be advised of other mitigations to reduce their risk of becoming infected and be provided with information on access to treatments should they test positive for infection.